The revolution in oncology brought by immunotherapies shows no sign of abating, with a record number of approvals last year.
Research from GlobalData shows that 10 licenses for immuno-oncology products were granted in 2022.
Overall, the number of approvals has increased by 150% between 2014 and 2022, with Bristol-Myers Squibb’s (NYSE: BMY) Yervoy (ipilimumab) the first to get the ball rolling on what has been a transformational approach to treating cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze